Literature DB >> 21188650

Therapeutic perspectives in atopic dermatitis.

Laurent Misery1.   

Abstract

Therapy of atopic dermatitis should comprise emollients, topical glucocorticosteroids, or calcineurin inhibitors, phototherapies, immunosuppressants like cyclosporin A, and other treatments. All these treatments should be improved, thanks to research. But new therapeutic perspectives should be given by topical anti-inflammatory substances, selective glucocorticoid receptor agonists, probiotics, interferon γ, TNFα inhibitors, inhibition of T cells or B cells, inhibition of IgE binding, and many other possibilities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21188650     DOI: 10.1007/s12016-010-8226-y

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  35 in total

1.  Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.

Authors:  H Schäcke; T M Zollner; W D Döcke; H Rehwinkel; S Jaroch; W Skuballa; R Neuhaus; E May; U Zügel; K Asadullah
Journal:  Br J Pharmacol       Date:  2009-05-06       Impact factor: 8.739

Review 2.  Asthma.

Authors:  Christopher H Fanta
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

3.  The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study.

Authors:  Ramon Grimalt; Valérie Mengeaud; Frédéric Cambazard
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

4.  Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Authors:  H-H Lee; I-H Song; M Friedrich; A Gauliard; J Detert; J Röwert; H Audring; S Kary; G-R Burmester; W Sterry; M Worm
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

Review 5.  Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.

Authors:  Diamant Thaçi; Rebekka Salgo
Journal:  Clin Dermatol       Date:  2010 Jan-Feb       Impact factor: 3.541

6.  Anti-CD20 (rituximab) treatment improves atopic eczema.

Authors:  Dagmar Simon; Susanne Hösli; Ganna Kostylina; Nikhil Yawalkar; Hans-Uwe Simon
Journal:  J Allergy Clin Immunol       Date:  2008-01       Impact factor: 10.793

7.  Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.

Authors:  Lee E Sheinkopf; Asif W Rafi; LanAnh T Do; Roger M Katz; William B Klaustermeyer
Journal:  Allergy Asthma Proc       Date:  2008 Sep-Oct       Impact factor: 2.587

8.  Atopic dermatitis: impact on the quality of life of patients and their partners.

Authors:  L Misery; A Y Finlay; N Martin; S Boussetta; C Nguyen; E Myon; C Taieb
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

9.  Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study.

Authors:  A C Davaine; A Saraux; S Prigent; I Kupfer-Bessaguet; D Roswag; P Plantin; P Schoenlaub; F Talarmin; A Zagnoli; L Misery
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-08-18       Impact factor: 6.166

10.  Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

Authors:  Danielle K Moul; Shannon B Routhouska; Maria R Robinson; Neil J Korman
Journal:  J Am Acad Dermatol       Date:  2008-04-18       Impact factor: 11.527

View more
  12 in total

Review 1.  Interferons: Success in anti-viral immunotherapy.

Authors:  Fan-ching Lin; Howard A Young
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

Review 2.  Atopic dermatitis: new trends and perspectives.

Authors:  Laurent Misery
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

3.  The practical understanding and treatment of asthma.

Authors:  M Eric Gershwin; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

Review 4.  Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema.

Authors:  Katherine Altman; Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

5.  Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial.

Authors:  Hyeon-Jong Yang; Taek Ki Min; Hae Won Lee; Bok Yang Pyun
Journal:  Allergy Asthma Immunol Res       Date:  2013-12-12       Impact factor: 5.764

Review 6.  Oral Aspects Identified in Atopic Dermatitis Patients: A Literature Review.

Authors:  Aline Domingues Tavares Oliveira; Camila Stofella Sodré; Dennis de Carvalho Ferreira; Eliane de Dios Abad; Simone Saintive; Márcia Ribeiro; Fernanda Sampaio Cavalcante; Bruna Piciani; Lucio Souza Gonçalves
Journal:  Open Dent J       Date:  2018-05-31

7.  Umbilical cord-derived mesenchymal stem cell extracts ameliorate atopic dermatitis in mice by reducing the T cell responses.

Authors:  Ji-Young Song; Hyo Jeong Kang; Hyun Min Ju; Arum Park; Hyojung Park; Joon Seok Hong; Chong Jai Kim; Jae-Yoon Shim; Jinho Yu; Jene Choi
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

8.  Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis.

Authors:  K Na; H S Yoo; Y X Zhang; M-S Choi; K Lee; T G Yi; S U Song; M-S Jeon
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

9.  Beneficial effects of melittin on ovalbumin-induced atopic dermatitis in mouse.

Authors:  Woon-Hae Kim; Hyun-Jin An; Jung-Yeon Kim; Mi-Gyeong Gwon; Hyemin Gu; Minji Jeon; Woo Jung Sung; Sang Mi Han; Sok Cheon Pak; Min-Kyung Kim; Kwan-Kyu Park
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

10.  Therapeutic effects of bee venom and its major component, melittin, on atopic dermatitis in vivo and in vitro.

Authors:  Hyun-Jin An; Jung-Yeon Kim; Woon-Hae Kim; Mi-Gyeong Gwon; Hye Min Gu; Min Ji Jeon; Sang-Mi Han; Sok Cheon Pak; Chong-Kee Lee; In Sook Park; Kwan-Kyu Park
Journal:  Br J Pharmacol       Date:  2018-11-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.